Abstract
Adverse pathologic features - including positive surgical margins, extracapsular extension, and seminal vesicle invasion - are common findings at radical prostatectomy for clinically localised disease. In the absence of further treatment, patients with such features are at high risk of biochemical and local recurrence and the development of metastatic disease. Radiotherapy is the only known curative treatment modality in patients with locally recurrent disease. Its optimal use following surgery, however, is controversial. In this review, the evidence for immediate (adjuvant) and selective early salvage approaches to postoperative radiotherapy are presented. The results of three randomized controlled trials comparing adjuvant radiotherapy to observation are discussed. The trial with the longest follow-up now demonstrates that, compared to a policy of observation, adjuvant radiotherapy prolongs overall survival and prevents distant metastases. It is not clear, however, whether this survival advantage would remain if adjuvant radiotherapy were compared to a strategy of close monitoring with salvage radiotherapy instituted at the time of biochemical failure. A selective salvage strategy has the advantage of avoiding ‘unnecessary’ radiotherapy, and its toxicity, for those patients destined not to fail after surgery. Large-scale randomized controlled trials comparing these two approaches are underway.
Keywords: Prostate cancer, radiotherapy, radical prostatectomy, adjuvant therapy, salvage therapy
Current Cancer Therapy Reviews
Title: Postoperative Radiotherapy After Radical Prostatectomy: Adjuvant or Salvage?
Volume: 7 Issue: 3
Author(s): Scott C. Morgan and Chris C. Parker
Affiliation:
Keywords: Prostate cancer, radiotherapy, radical prostatectomy, adjuvant therapy, salvage therapy
Abstract: Adverse pathologic features - including positive surgical margins, extracapsular extension, and seminal vesicle invasion - are common findings at radical prostatectomy for clinically localised disease. In the absence of further treatment, patients with such features are at high risk of biochemical and local recurrence and the development of metastatic disease. Radiotherapy is the only known curative treatment modality in patients with locally recurrent disease. Its optimal use following surgery, however, is controversial. In this review, the evidence for immediate (adjuvant) and selective early salvage approaches to postoperative radiotherapy are presented. The results of three randomized controlled trials comparing adjuvant radiotherapy to observation are discussed. The trial with the longest follow-up now demonstrates that, compared to a policy of observation, adjuvant radiotherapy prolongs overall survival and prevents distant metastases. It is not clear, however, whether this survival advantage would remain if adjuvant radiotherapy were compared to a strategy of close monitoring with salvage radiotherapy instituted at the time of biochemical failure. A selective salvage strategy has the advantage of avoiding ‘unnecessary’ radiotherapy, and its toxicity, for those patients destined not to fail after surgery. Large-scale randomized controlled trials comparing these two approaches are underway.
Export Options
About this article
Cite this article as:
C. Morgan Scott and C. Parker Chris, Postoperative Radiotherapy After Radical Prostatectomy: Adjuvant or Salvage?, Current Cancer Therapy Reviews 2011; 7 (3) . https://dx.doi.org/10.2174/157339411796234898
DOI https://dx.doi.org/10.2174/157339411796234898 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Evaluation of HIF-1α Gene Variation and Determination of Its Frequency and Association with Breast Cancer Susceptibility in Saudi Arabia
Endocrine, Metabolic & Immune Disorders - Drug Targets The Importance of Integrating SNP and Cheminformatics Resources to Pharmacogenomics
Current Drug Metabolism Novobiocin Analogs as Potential Anticancer Agents
Mini-Reviews in Medicinal Chemistry Targeted Therapies in the Treatment of Advanced Renal Cell Carcinoma
Recent Patents on Anti-Cancer Drug Discovery Current Perspectives on Novel Drug Delivery Systems and Therapies for Management of Prostate Cancer: An Inclusive Review
Current Drug Targets Recent Advances in the Treatment of Helicobacter pylori Infection
Recent Patents on Anti-Infective Drug Discovery Alpha-1 Antitrypsin: It’s Role in Health and Disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases
Anti-Cancer Agents in Medicinal Chemistry Allosteric Modulators for Adenosine Receptors: An Alternative to the Orthosteric Ligands
Current Topics in Medicinal Chemistry Ruthenium(II) Complexes as Potential Apoptosis Inducers in Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Anti-Cancer Agent-Induced Nephrotoxicity
Anti-Cancer Agents in Medicinal Chemistry Novel Applications of Recombinant Lactic Acid Bacteria in Therapy and in Metabolic Engineering
Recent Patents on Biotechnology An Overview on Fibroblast Growth Factors: Structural, Functional and Therapeutic Implications
Current Proteomics Hyperthermia Associated Osteonecrosis in Young Patients with Pelvic Malignancies
Anti-Cancer Agents in Medicinal Chemistry Mutation Mechanisms of Breast Cancer among the Female Population in China
Current Bioinformatics Exosomes: Natural Carriers for siRNA Delivery
Current Pharmaceutical Design Role of Anti-HER-2 Therapies in the Neo-Adjuvant Setting: Is Complete Pathological Response a Solid Surrogate?
Reviews on Recent Clinical Trials Recent Progress in Discovery and Development of Antimitotic Agents
Anti-Cancer Agents in Medicinal Chemistry Possible Involvement of Angiogenesis in Chronic Liver Diseases: Interaction Among Renin-Angiotensin-Aldosterone System, Insulin Resistance and Oxidative Stress
Current Medicinal Chemistry Extracts of <i>Anogeissus leiocarpus and Dillenia indica</i> Inhibit the Growth of MCF-7 Breast Cancer and COV434 Granulosa Tumor Cells by Inducing Apoptosis and Autophagy
Current Bioactive Compounds